期刊
DRUG DISCOVERY TODAY
卷 24, 期 2, 页码 606-615出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.11.007
关键词
-
资金
- Agency for Healthcare Research and Quality [K12HS023000]
- Brain and Behavior Research Foundation
- Robert E. Leet and Clara Guthrie Patterson Trust
- American Foundation for Suicide Prevention
- West Haven VA National Center for PTSD
- State of CT Department of Mental Health and Addiction Services
- Yale-New Haven Hospital
Mood disorders represent the largest cause of disability worldwide. The monoaminergic deficiency hypothesis, which has dominated the conceptual framework for researching the pathophysiology of mood disorders and the development of novel treatment strategies, cannot fully explain the underlying neurobiology of mood disorders. Mounting evidence collected over the past two decades suggests the amino acid neurotransmitter systems (glutamate and GABA) serve central roles in the pathophysiology of mood disorders. Here, we review progress in the development of compounds that act on these systems as well as their purported mechanisms of action. We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC301 /MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (R04917523), decoglurant (RG-1578/R04995819), tulrampator (CX1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据